An oxidant/antioxidant imbalance in favour of oxidants appears to occur in chronic cor pulmonale (CCP). Oxidative stress could also be a critical event in the pathogenesis of this condition. Trimetazidine (TMZ) has antioxidant properties and may affect the utilization of oxygen radicals. We investigated the effect of TMZ (20 mg three times daily, orally) on activities of erythrocyte malondialdehyde (MDA) and catalase (eCAT), erythrocyte and plasma glutathione peroxidase (GSH-Px) and plasma superoxide dismutase (pSOD) in CCP patients. We also assessed changes in plasma levels of brain natriuretic peptide (BNP) with TMZ therapy.
Introduction
Chronic cor pulmonale (CCP) refers to the pathological effect of lung dysfunction on the right side of the heart. Generally, pulmonary hypertension is the link between changes in right ventricular structure, function and lung pathology. The common denominator in each case is right ventricular dysfunction, with subsequent decreases in stroke and cardiac output. CCP is estimated to account for the 6 -7% of all types of adult heart disease that involve chronic obstructive pulmonary disease due to chronic bronchitis or emphysema and asthma. 1 The underlying sub-cellular and molecular events that lead to heart failure appear to be multifactorial and complex. Some of these factors are defects in the production and utilization of high-energy phosphates, abnormalities in excitationcontraction coupling and calcium movements, down-regulation of β-adrenergic receptors, alterations in geometry and structure, peroxidation of oxygen free radicals and lipids, 2 -10 and apoptosis. 11 It is not clear which of these factors are the primary ones responsible for the initiation of the pathogenesis and which are the consequences of heart dysfunction. In this regard, significant evidence supporting the role of reactive oxygen species (ROS) and oxidative stress in chronic pathological states of the myocardium has been presented. 7, 8, 12, 13 Antioxidant enzymes such as glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) and catalase (CAT) play an important role in the detoxification of ROS generated under normal metabolic conditions. The total antioxidant status of erythrocyte and plasma is reduced in CCP. 7, 8, 12, 13 Plasma brain natriuretic peptide (BNP), a cardiac hormone secreted mainly by the ventricles of the heart, 14, 15 has been used as a non-invasive marker of left ventricular dysfunction and a prognostic indicator in a variety of patients with left-sided heart failure. 16 -18 Plasma BNP increases in proportion to the degree of right ventricular dysfunction in pulmonary hypertension. 19 Trimetazidine (2,3,4-trimethoxybenzylpiperazine dihydrochloride, TMZ) is a clinically effective anti-anginal agent that improves the contractile response of chronically dysfunctional myocardium. This effect is associated with improvements in left ventricular function. There are several possible mechanisms of action by which TMZ promotes the preservation of membrane structures and cellular function, including: limitation of intracellular acidosis; prevention of excessive production of free radicals; inhibition of the inflammatory reaction; and an anti-platelet effect. TMZ decreases the content of lipid peroxidation products during intensification of ROS formation under conditions of ischaemia-reperfusion. 20 -22 Several studies have looked at the antioxidant effect of TMZ but none has looked at the effect of TMZ on the increase in ROS and on plasma BNP levels in patients with CCP. The objective of this study was to investigate the effect of oral administration of TMZ on oxidative stress and plasma BNP levels of patients with CCP.
Patients and methods

PATIENTS
This study was undertaken in patients attending the Nümune Hospital in Erzurum, Turkey, who had been diagnosed with CCP according to World Health Organization criteria. After baseline measurements were taken, the patients were randomly divided into two treatment groups and a control group of healthy people was also recruited. Group A comprised patients receiving routine CCP treatment (namely, an optimal combination of oral vasodilators, supplementary oxygen, cardiac glycosides, theophylline, anti-coagulation agents and diuretics). Group B comprised CCP patients receiving the routine treatments listed above plus TMZ at a dosage of 20 mg three times daily, orally, for 3 months. Groups A and B received treatment for 3 months, at which point repeat evaluations were performed.
METHODS
The study participants gave written informed consent, and the study was approved by the Atatürk University Medical Academy Ethics Committee.
Blood samples were collected in tubes containing lithium heparin (Geiner Labortechnik, Kremsmünster, Austria) at baseline in control patients, and before the commencement of treatment and after 3 months of medication in study participants. Each blood sample was divided into two portions. One portion was analysed for haematocrit, haemoglobin and reduced glutathione (GSH); the other was centrifuged, plasma was obtained, and the erythrocytes were washed in saline solution and haemolysed. GSH-Px activity in erythrocyte haemolysates and in plasma was measured spectrophotometrically by the method of Paglia and Valentine 23 with t-butylhydroperoxide as substrate. The values were expressed as IU/g haemoglobin (Hb) and IU/l, respectively. The GSH concentration in red blood cells was assayed by the method of Beutler, 24 and was expressed in µmol/g Hb. The SOD activity in plasma (pSOD) was measured according to the method of Paoletti and Mocali, 25 and was expressed in U/ml. Concentrations of malondialdehyde (MDA), which is an indicator of lipid peroxidation, in red cell haemolysate were measured using thiobarbituric acid-reactive substances, according to the method of Buege and Aust. 26 The values were expressed as nmol/g Hb. CAT activity was measured in haemolysates according to the method of Aebi. 27 Results were expressed as IU/mg Hb.
For BNP, blood was immediately transferred into a chilled glass tube containing disodium ethylenediamine tetraacetate (EDTA) (1 mg/ml) and aprotinin (500 IU/ml) and centrifuged immediately at 4°C. Plasma BNP levels were measured directly with a highly sensitive and specific immunoradiometric assay kit (Shionogi, Osaka, Japan). 28 
STATISTICAL ANALYSIS
Statistical analysis was carried out using Statgraphics software (Statgraphics Centurion, Version 15, Herndon, VA, USA) with analyses of means, SDs and simple linear regression. Differences between data sets were assessed using Student's t-test, and a P-value of < 0.05 was considered significant. The effects of therapy on plasma BNP levels were analysed by paired Student's t-test.
Results
PATIENTS
Sixty patients were randomly divided into the two treatment groups: Group A comprised 30 CCP patients (19 men, 11 women; mean age 58 years, range 46 -72 years) receiving routine treatment; Group B comprised 30 CCP patients (17 men and 13 women; mean age 61 years, range 49 -74 years) receiving routine treatment plus TMZ at a dose of 20 mg three times daily for 3 months. The control group comprised 24 healthy subjects (15 men and nine women; mean age 56 years, range 45 -74 years).
Values of all blood components measured are presented in Table 1 for the control group and for the CCP patients given routine treatment and routine treatment plus TMZ. Before treatment commenced, the erythrocyte GSH-Px activity level in both patient groups was similar to that in the control group, but the plasma GSH-Px activity level in the treatment groups was about half of that in the control group. Erythrocyte GSH-Px and plasma GSH-Px activity levels had not changed in the group receiving routine treatment at the end of the 3month treatment period, but erythrocyte GSH-Px had increased 2.5-fold and plasma GSH-Px had increased by approximately 50% in the group receiving routine treatment plus TMZ.
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E Bayram, C Atalay, H Kocatürk et al. Initially, the GSH level in both patient groups was about 60% of that in the control group. The level did not change during the 3-month treatment period in group A (routine treatment only), but in group B (routine treatment plus TMZ) it increased by 60%, reaching a level similar to that in the control group at the end of the treatment period.
Oxidative stress in chronic cor pulmonale
Plasma SOD enzyme activity levels showed great variation between the treatment groups by the end of the study. An increase of almost 50% was observed in pSOD enzyme activity in the patients in group B compared with the activity in this group at the beginning of the treatment period.
Erythrocyte CAT enzyme activity was lower in both patient groups compared with the control group, initially. After 3 months' treatment, although the CAT activity level did not change in group A, it increased by almost 30% in group B.
The erythrocyte MDA level was 22% higher than that of the control group in both patient groups, initially. After 3 months' treatment, no change had occurred in the group receiving only routine treatment, but there was a decrease to the level of the control group in the group receiving routine treatment plus TMZ (Table 1) .
BASELINE AND FOLLOW-UP BNP LEVELS
Baseline plasma BNP levels were significantly higher (P < 0.05) in the two treatment groups than in the healthy control group (Fig. 1) . The plasma BNP level decreased significantly after TMZ therapy (P < 0.001) but did not change significantly in the group receiving only routine treatment. At the end of 3 months of therapy, there was a significant difference in plasma BNP levels between the group receiving only routine treatment and the group also receiving TMZ (P < 0.05). 
Discussion
The development and progression of CCP disease have been associated with increased oxidative stress or reduced antioxidant resources. 7, 12, 13 Lipid peroxidation in erythrocytes is known to cause decreased cell survival, altered membrane lipid asymmetry, hypercoagulability and increased adhesiveness to the endothelium. 29 The marked increase in lipid peroxidation in erythrocytes observed in the patient with CCP is attributed to chronic inflammation and oxidant-antioxidant imbalance, which causes increased production of ROS. Cheng 30 showed that oxygen free radicals contribute to the physiopathological process of CCP. The present investigation was undertaken to assess the antioxidant role of TMZ in patients with CCP. TMZ is a well-established anti-ischaemic drug and has been used in the treatment of pathological conditions related to the generation of oxygen species. Various experimental studies have shown that TMZ prevents excessive release of free radicals, which are responsible for both the fall in the intracellular concentration of adenosine triphosphate (ATP) and the extracellular leakage of potassium. 31, 32 Maridonneau-Parini and Harpey 32 first demonstrated on human red blood cells that TMZ, administered at a therapeutic dose for 7 days, exerted a potent antioxidant effect. The drug significantly reduced both the loss of intracellular K + induced by oxygen free radicals (generated by phenazine methosulphate added to the medium) in red cells and the membrane content of peroxidated lipids. In this study, we showed that treatment with TMZ attenuated the lipid peroxide reaction markedly and increased the levels of antioxidant enzymes in patients with CCP. In our study, 3 months of therapy with TMZ sharply decreased levels of free radical oxidation products and MDA in patients with CCP.
Decreased activities of antioxidant enzymes (SOD, GSH-Px and CAT) may be due to inactivation caused by ROS. In the present investigation, it was observed that TMZ therapy could effectively normalize the activity of GSH-Px, CAT and SOD. This suggests that increased oxidative stress during CCP was controlled. The pSOD, erythrocyte CAT and GSH-Px (both erythrocyte and plasma) remained low in patients receiving routine therapy alone. The GSH level increased after TMZ therapy, whereas the activities of antioxidant enzymes did not increase in patients receiving only routine treatment. These results are in agreement with those of other workers. 33, 34 Guarnieri and Muscari et al. 34 produced a condition of the heart by injection of monocrotaline in rats; this drug decreases mitochondrial function and increases the generation of mitochondrial O 2 ·radicals and lipoperoxidative damage. Concomitant treatment of animals with TMZ (2.5 mg/kg) improved cardiac mitochondrial activity. Their results indicated that cardiac submitochondrial particles in rats treated with TMZ produced less O 2 ·than those from rats treated with monocrotaline alone. They also demonstrated that TMZ exerted antioxidant properties in their model. 34 Brain natriuretic peptide has been shown to be a biochemical marker of the severity of congestive heart failure. Pressure or volume overload of both ventricles due to different underlying conditions induces BNP release. Left ventricular systolic dysfunction 35, 36 and left ventricular diastolic dysfunction 37 are well-known conditions associated with BNP secretion. In addition to left ventricular dysfunction, there are reports of volume and pressure overload of the right ventricle, Oxidative stress in chronic cor pulmonale leading to slightly or moderately elevated BNP levels. 19 We are aware of only a few papers reporting the association of BNP elevation with pulmonary hypertension (primary, thromboembolic, or as a consequence of chronic obstructive pulmonary disease). The study of Nagaya et al. 19 demonstrated that plasma BNP correlated inversely with right ventricular ejection fraction in patients with pulmonary hypertension. Thus, plasma BNP may be suitable for the evaluation of right ventricular dysfunction and thereby the prediction of death in patients with CCP. Our study showed that the plasma BNP level decreased significantly after TMZ therapy, but it did not decrease significantly with only routine treatment.
It is possible that TMZ affects and maintains cellular homeostasis, preserves electrical and contractile activity, and limits cytolysis; these effects have been ascribed to a protective action on energy metabolism, limiting intracellular acidosis.
In conclusion, we found that TMZ therapy resulted in a decrease in oxidative stress and a decrease in the plasma BNP level, a prognostic indicator of heart failure. We speculate that TMZ might be used in CCP patients. Detailed studies are required to explore this subject.
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